Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.

Abstract: The invention relates to COnditional Bispecific Redirected Activation constructs, or COBRAs, that are administered in an active pro-drug format. Upon exposure to tumor proteases, the constructs are cleaved and activated, such that they can bind both tumor target antigens (TTAs) as well as CD3, thus recruiting T cells expressing CD3 to the tumor, resulting in treatment.

Abstract: The present invention provides, among other aspects, methods and compositions for treating a central nervous system (CNS) disorder by delivering a therapeutically effective amount of a composition of pooled human immunoglobulin G (IgG) to the brain via intranasal administration of the composition directly to the olfactory epithelium of the nasal cavity. In particular, methods and compositions for treating Alzheimer's disease are provided.

Abstract: The present invention relates to compound (I) or a salt thereof which has a ROR?t inhibitory action. In the formula (I), each symbol is as defined in the specification.

Abstract: Methods for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK in a sample are provided herein. Such methods may comprise treating a biological sample with a protease to generate a plurality of digested peptides, and measuring one or more signature peptides, which are indicative of cleaved HMWK and/or full-length HMWK.

Abstract: The present invention provides a composition comprising a compound of formula (I) or a physiologically acceptable salt thereof, in which the compound of formula (I) or a physiologically acceptable salt thereof has a HPLC purity of ?90%; wherein R1, R2, X and n are as defined herein. The present invention further provides use of the composition according to the present invention for preparing and/or purifying a composition comprising a salt of the compound of formula (I), and a method for treating a disease caused by a coronavirus which comprises administering the composition of the present invention to a subject. The composition of the present invention comprises the compound of formula (I) with high purity, and has good fluidity and anti-caking property; moreover, the claimed composition comprising the compound of formula (I)) with high purity is more suitable for preparing a composition comprising a salt of the compound of formula (I) with higher purity.

Abstract: A method (500) for managing nausea includes receiving, from one or more monitoring devices (200), patient parameter data (212) of a patient (10). The patient parameter data is collected by the one or more monitoring devices. The method also includes determining, based on the patient parameter data of the patient, whether the patient is experiencing or about to experience an episode of nausea. When the patient is experiencing or about to experience an episode of nausea, the method also includes communicating one or more therapy signals (302, 304, 306, 308) to a receiver device (12, 21, 400) in communication with the computing device.

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Abstract: The invention provides a composition of glucocerebrosidase, such as velaglucerase alfa, and isofagomine, in a molar ratio of at least about 1:2.5. Also provided is a use of the composition for treatment of a disorder related to a dysfunction in a GCase pathway. The disorder could be a lysosomal storage disease, such as Gaucher disease, Fabry disease, Pompe disease, a mucopolysaccharidoses, or multiple system atrophy. The disorder could also be a neurodegenerative disorder, such as Parkinson disease, Alzheimer's disease, or Lewy body dementia. The composition can have 0.5 to 5.0 mg/kg of glucocerebrosidase and isofagomine in at least about a 3-fold molar excess to the glucocerebrosidase. The composition can be administered intravenously or subcutaneously.

Abstract: The present invention provides means for producing a parathyroid gland organoid. A culture method of the present invention includes a cell population containing a parathyroid gland cell in a ratio of 50% or more, and a mesenchymal cell in a ratio of 10% or more; and a step of culturing the cell population.

Abstract: A compound of formula (I), or a salt thereof that may have an antagonistic action against an NMDA receptor that includes an NR2B subunit and may be useful as a prophylactic or therapeutic agent for depression, bipolar disorder, migraine, pain, a symptom peripheral to dementia, or the like.

Abstract: Disclosed herein are evacuated blood collection tubes comprising protease inhibitor cocktails in liquid form and uses thereof for assessing features associated with the contact system in a subject, including the endogenous level of contact system activation, the endogenous level of a drug that targets a component of contact system during treatment, and/or the immunogenicity of such a drug.

Abstract: The present invention provides a therapeutic agent for an immune/inflammatory disease comprising an anti-human TIGIT antibody, which activates a suppressive immune checkpoint molecule (TIGIT), as an active ingredient. Also, provided is an antibody having the following characteristics a) and b): a) the third CDR of heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 4 b) the third CDR of light chain variable region comprises the amino acid sequence of SEQ ID NO: 6.

Abstract: The invention relates to an affinity resin functionalized with small molecule inhibitors of glycoside-cleaving enzymes, e.g., ?-galactosidase A (?-Gal A), glucocerebrosidase (GCB), ?-galactosidase, and acid alpha-glucosidase (GAA), and a method for purifying glycoside-cleaving enzymes produced in a cell line using the small molecule inhibitor-functionalized affinity resin.

Abstract: The present disclosure provides a crystal form comprising a compound of Formula (I) and fumaric acid, wherein the crystal form satisfies at least one of the following conditions: (1) a particle size D90 of the active pharmaceutical ingredient ranges from about 5 ?m to about 60 ?m; and (2) a particle size D50 of the active pharmaceutical ingredient does not exceed about 30 ?m; a pharmaceutical composition containing the crystal form, and a method for treating coronavirus-induced diseases by using the crystal form. The crystal form of the present disclosure enables the pharmaceutical composition containing the crystal form to have advantages such as a higher dissolution rate, a higher dissolution, and the like.

Abstract: The present invention provides a composition comprising a compound of formula (I) or a physiologically acceptable salt thereof, in which the compound of formula (I) or a physiologically acceptable salt thereof has a HPLC purity of ? 90%; wherein R1, R2, X and n are as defined herein. The present invention further provides use of the composition according to the present invention for preparing and/or purifying a composition comprising a salt of the compound of formula (I), and a method for treating a disease caused by a coronavirus which comprises administering the composition of the present invention to a subject. The composition of the present invention comprises the compound of formula (I) with high purity, and has good fluidity and anti-caking property; moreover, the claimed composition comprising the compound of formula (I)) with high purity is more suitable for preparing a composition comprising a salt of the compound of formula (I) with higher purity.

Abstract: Provided herein are methods and kits for analyzing a biological sample obtained from a subject having, suspected of having, or being at risk for a disease associated with the contact activation system.

Abstract: Systems and methods providing a clotting factor VIII dosing regimen are disclosed. The systems and methods include determining an estimated pharmacokinetic profile of a patient using a Bayesian model of pharmacokinetic profiles of sampled patients. The systems and methods can determine a first dosing regimen for a first dosing interval including (i) a first dosage and (ii) a first therapeutic plasma protein level in the patient varying over time based at least upon the estimated pharmacokinetic profile. The systems and methods can determine a second dosing regimen for a second dosing interval including (i) a second dosage and (ii) a second therapeutic plasma protein level in the patient varying over time. The estimated pharmacokinetic profile can be adjusted based on previous patient treatments. Further, a user can select which days a dosage is to be applied such that the protein level does not fall below a target trough.

Abstract: A device is provided for pooling a fluid from a container unit having at least one container, and includes an inlet port having at least one inlet channel configured for receiving the fluid or ambient air, and an outlet port having at least one outlet channel configured for delivering the fluid to an attachment. Both inlet and outlet ports are disposed on the device. A cavity is provided for accommodating insertion of the container unit for pooling the fluid from the at least one container. At least one spike is disposed in the cavity and configured for puncturing a stopper of the at least one container when the container unit transitions from an upper position to a lower position.